Auris Medical’s Tinnitus Candidate Keyzilen Fails Second Phase III Trial

Keyzilen misses primary efficacy endpoint of statistically significant improvement in Tinnitus Functional Score from baseline to day 84 in participants treated with the drug compared to those treated with placebo